NETWORK PHARMACOLOGY, MOLECULAR DOCKING AND IN-VITRO ANTI-INFLAMMATORY ACTIVITY OF FORMONONETIN
International Journal of Drug Delivery Technology · 08.06.2026 · 16 (48s)
DOI: 10.25258/ijddt.16.48s.97 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 08.06.2026. Verfasst von Shivam Biswas und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Inflammation is a complex biological response implicated in the pathogenesis of numerous chronic disorders, and the limitations associated with conventional anti-inflammatory therapies necessitate the development of safer and multitarget therapeutic alternatives. Formononetin, a naturally occurring O-methylated isoflavone, has shown promising pharmacological activities, including anti-inflammatory effects. The present study aimed to investigate the antiinflammatory potential and underlying molecular mechanisms of Formononetin using an integrated network pharmacology, molecular docking, ADMET prediction, and in vitro validation approach. A total of 177 Formononetinassociated targets and 17,010 inflammation-related genes were retrieved from public databases, among which 144 overlapping targets were identified. Protein–protein interaction analysis revealed TNF, EGFR, HSP90AA1, BCL2, ESR1, PTGS2, HSP90AB1, PPARG, GSK3B, and MCL1 as key hub genes involved in Formononetin-mediated antiinflammatory activity. Gene Ontology and KEGG enrichment analyses indicated significant involvement of pathways associated with arachidonic acid metabolism, inflammatory mediator regulation of TRP channels, lipid and atherosclerosis, estrogen signaling, and oxidative stress responses. ADMET analysis demonstrated favorable druglikeness, high gastrointestinal absorption, acceptable pharmacokinetic properties, and moderate safety. Molecular docking studies confirmed strong binding affinities of Formononetin with major hub targets, particularly PPARG (−9.5 kcal/mol), HSP90AA1 (−9.3 kcal/mol), HSP90AB1 (−9.1 kcal/mol), and PTGS2 (−9.0 kcal/mol), indicating stable ligand–protein interactions. In vitro studies in LPS-stimulated macrophages showed that Formononetin was noncytotoxic up to 100 µg/mL and significantly inhibited nitric oxide production in a concentration-dependent manner, with maximum inhibition of 80% at 200 µg/mL. Collectively, these findings demonstrate that Formononetin exerts potent anti-inflammatory effects through modulation of multiple molecular targets and pathways, supporting its potential as a promising natural therapeutic candidate for inflammation-associated disorders.
Zitieren
APA
Biswas, S., & Waghmare, A. (2026). NETWORK PHARMACOLOGY, MOLECULAR DOCKING AND IN-VITRO ANTI-INFLAMMATORY ACTIVITY OF FORMONONETIN. International Journal of Drug Delivery Technology, 16(48s). https://doi.org/10.25258/ijddt.16.48s.97
Vancouver
Biswas S, Waghmare A. NETWORK PHARMACOLOGY, MOLECULAR DOCKING AND IN-VITRO ANTI-INFLAMMATORY ACTIVITY OF FORMONONETIN. International Journal of Drug Delivery Technology. 2026;16(48s). doi:10.25258/ijddt.16.48s.97
BibTeX
@article{Biswas2026,
author = {Biswas, Shivam and Waghmare, Atish},
title = {NETWORK PHARMACOLOGY, MOLECULAR DOCKING AND IN-VITRO ANTI-INFLAMMATORY ACTIVITY OF FORMONONETIN},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {48s},
doi = {10.25258/ijddt.16.48s.97}
}
EUVIMED